Nyxoah (NYXH) Q1 2026: U.S. Revenue Jumps 25% as Genio Adoption Accelerates

2026-05-12 | By EarningsIQ Research

Nyxoah’s second full U.S. commercial quarter delivered a 25% sequential revenue surge, driven by expanding Genio system adoption and robust execution across high-volume accounts. Clarity on reimbursement and a disciplined cash management approach underpin management’s confidence in accelerating growth through year-end. Investors should monitor the ramp in trained surgeons, account activations, and the rollout of Genio 2.2 as levers for margin and market share progression.

Summary

• Genio Adoption Momentum: U.S. market share and account activation are expanding rapidly as surgeon training scales.
• Reimbursement Certainty Secured: Commercial and Medicare coverage is stable, supporting volume ramp and de-risking near-term execution.
• Margin Inflection in Sight: Cost discipline and Genio 2.2 set up structural gross margin improvement by 2027.

Business Overview

Nyxoah develops and commercializes Genio, a hypoglossal nerve stimulation (HGNS) system for obstructive sleep apnea (OSA), a chronic sleep disorder. The company generates revenue through device sales and related disposables, with its business split between the U.S. (primary growth engine) and international markets (notably Germany, the Middle East, and select European countries). Key segments include device sales, surgeon training, and account activation, with a focus on high-volume implant centers and partnerships with sleep medicine physicians.

Performance Analysis

Nyxoah’s Q1 2026 results highlight a pivotal inflection in U.S. commercial execution, delivering 25% sequential U.S. net revenue growth and 13% worldwide sequential growth. Key drivers included a substantial increase in active accounts, a doubling of patient prior authorizations in the funnel, and a sharp ramp in trained surgeons and sales reps, enabling expanded coverage of targeted high-volume sites.

Gross margin compressed to 57%, down from 62% YoY, due to temporary production yield issues, which management asserts have been resolved. Operating expenses rose as expected, reflecting focused U.S. commercial investment, while non-GAAP cash OpEx was held flat sequentially, showcasing disciplined cost allocation from R&D and G&A into sales and marketing. International operations maintained revenue stability despite typical Q1 seasonality, with Germany demonstrating the viability of the break-even model three years post-launch.

• U.S. Commercial Ramp: 62 new surgeons trained and 34 new accounts activated, pushing active accounts to 91 of 125 targets.
• Patient Funnel Expansion: Prior authorization submissions rose to 241 at quarter-end, more than doubling from Q4’s 116.
• Cash Management Discipline: Non-GAAP cash OpEx decreased sequentially, while incremental salesforce investment was offset by R&D and G&A reductions.

Quarter-end cash of €25.9M and a planned €13.8M EIB loan draw provide runway for continued U.S. expansion and Genio 2.2 development. Management targets revenue break-even below €150M, underpinned by a path to 80%+ gross margins as new cost-reduction initiatives scale.

Executive Commentary

Strategic Positioning

1. U.S. Commercial Expansion

Nyxoah’s primary strategic lever is rapid U.S. commercial scale, with investments in salesforce expansion, surgeon training, and account activation. By Q2, 40 fully trained reps will cover 200 of 400 targeted high-volume accounts, up from 25 reps covering 125 accounts at launch. Market research confirms high physician receptivity, with 88% of ENTs valuing multiple HGNS options and all Genio-trained surgeons planning to adopt the system.

2. Reimbursement De-Risking

Reimbursement clarity across commercial and Medicare payers is a key differentiator, with 100% prior authorization approval rates and stable CPT/C-code frameworks through at least 2027. CMS’s C8011 code and commercial dual-code coverage (CPT 64568 and 64582) remove a major barrier to adoption, while the WISER program supports AI-driven Medicare approvals.

3. Product Innovation and Margin Roadmap

Genio 2.2, a next-generation device suite with a low-cost disposable patch and upgraded software, is slated for early 2027 launch. This upgrade is expected to drive a step-change in gross margins into the low 70% range, with further upside from volume-driven manufacturing cost reductions. Management targets 80%+ gross margins long-term, aligning with break-even ambitions below €150M revenue.

4. International Platform Leverage

International operations, led by Germany, contribute stable revenue and validate the break-even playbook, while new market entries (UK, Netherlands, Middle East) demonstrate scalable adoption potential. Financial discipline internationally frees up resources for U.S. growth, without undermining global presence.

Key Considerations

This quarter, Nyxoah delivered a tangible shift in commercial momentum, underpinned by operational discipline and a de-risked reimbursement environment. Success in the U.S. will hinge on continued account and surgeon ramp, patient funnel conversion, and execution of the Genio 2.2 upgrade.

Key Considerations:

• Salesforce Productivity Ramp: Newly trained reps are expected to drive sequential acceleration in procedure volumes as their territories mature.
• Patient Prior Authorization Funnel: The more than doubling of prior auth submissions signals robust future implant volumes and revenue conversion potential.
• Margin Recovery Trajectory: Resolution of Q1 production yield issues and the upcoming Genio 2.2 launch are pivotal for restoring and expanding gross margins.
• Reimbursement Policy Stability: Ongoing CPT code evolution through 2028 is being closely monitored, but near-term risk is minimal given CMS and commercial payer clarity.

Risks

Key risks include execution on the rapid U.S. commercial scale-up, where delays in surgeon adoption, account activation, or patient conversion could slow revenue realization. Gross margin recovery depends on successful resolution of manufacturing issues and timely Genio 2.2 launch, while longer-term reimbursement code changes post-2027 could introduce complexity. Competitive dynamics, particularly with larger incumbent devices, may pressure share gains if differentiation is not sustained.

Forward Outlook

For Q2 2026, Nyxoah guided to:

• U.S. net revenue growth of 25% to 30% sequentially

For full-year 2026, management raised guidance to:

• Worldwide net revenue of €36M to €40M
• Gross margin of 60% to 62%
• Total operating expenses of €97M to €99M
• Non-GAAP cash OpEx of €88M to €90M

Management highlighted:

• Back-half acceleration as new sales reps and trained surgeons drive increased productivity
• Reimbursement de-risking and stable payer environment supporting sustained adoption

Takeaways

• Commercial Ramp is Delivering: U.S. revenue growth, a swelling patient funnel, and more active accounts underscore strong execution against expansion targets.
• Margin Inflection Hinges on Genio 2.2: Resolving production issues and launching the upgraded system are critical for gross margin expansion and break-even progress.
• Watch for Back-Half Acceleration: Further productivity gains from the expanded salesforce and surgeon base should drive sequential revenue acceleration and validate the U.S. scale thesis.

Conclusion

Nyxoah enters Q2 with commercial momentum, reimbursement clarity, and disciplined financial management, positioning the company for sustained U.S. growth and a path to profitability. Execution on Genio 2.2 and continued patient funnel conversion will be decisive for realizing long-term margin and market share ambitions.

Industry Read-Through

Nyxoah’s results provide a read-through for the broader medtech sector, demonstrating that reimbursement clarity and robust physician engagement are critical for new device adoption in the U.S. market. The company’s success with account activation and patient funnel management highlights the importance of commercial execution and targeted resource allocation. Gross margin headwinds tied to scaling production and product innovation are common challenges, with step-change improvements often tied to next-generation launches. Other device makers targeting high-volume, procedure-based markets should note the strategic value of payer engagement and the operational discipline required to achieve break-even at scale.

NYXH Healthcare Medical Devices Commercialization Reimbursement Gross Margin Sleep Apnea Genio